Please use this identifier to cite or link to this item: https://doi.org/10.1007/s10549-011-1555-6
Title: Keratin 15, transcobalamin I and homeobox gene Hox-B13 expression in breast phyllodes tumors: Novel markers in biological classification
Authors: Chong, L.Y.-Z.
Cheok, P.Y.
Tan, W.-J.
Thike, A.A.
Allen, G.
Ang, M.K.
Ooi, A.S.
Tan, P. 
Teh, B.T.
Tan, P.H.
Keywords: HOXB13
Keratin 15
Malignant
Phyllodes tumor
Transcobalamin I
Issue Date: Feb-2012
Citation: Chong, L.Y.-Z., Cheok, P.Y., Tan, W.-J., Thike, A.A., Allen, G., Ang, M.K., Ooi, A.S., Tan, P., Teh, B.T., Tan, P.H. (2012-02). Keratin 15, transcobalamin I and homeobox gene Hox-B13 expression in breast phyllodes tumors: Novel markers in biological classification. Breast Cancer Research and Treatment 132 (1) : 143-151. ScholarBank@NUS Repository. https://doi.org/10.1007/s10549-011-1555-6
Abstract: Breast phyllodes tumors are rare neoplasms which present challenges for histological classification. Microscopic features are not always predictive of clinical behavior, and scarce data exist on the prognostic role of biological markers. Our study evaluated a series of 145 phyllodes tumors diagnosed at the Department of Pathology, Singapore General Hospital between 2006 and 2009, incorporating 91 (62.8%) benign, 40 (27.6%) borderline, and 14 (9.7%) malignant phyllodes tumors. Antibodies to keratin 15 (KRT15), transcobalamin I (TCN1), and homeobox gene Hox-B13 (HOXB13) were applied to sections cut from tissue microarray blocks. KRT15 and TCN1 positivity was defined when there was reactivity of 1% or more stromal cells, while HOXB13 positivity was defined using a H-score of 100 and above. Positive immunohistochemical expression for KRT15, TCN1, and HOXB13 was seen in 21 (14.5%), 96 (66.2%), and 66 (45.5%) of tumors, respectively. Stromal expression of KRT15, TCN1, and HOXB13 was significantly correlated with tumor grade (P < 0.001, P < 0.001, P = 0.012), stromal hypercellularity (P = 0.005, P < 0.001, P = 0.023), mitotic activity (P < 0.001), and microscopic borders (P = 0.006, P < 0.001, P = 0.011). Co-expression of TCN1 and HOXB13 was seen in 21 of 91 (23.1%) benign, 18 of 40 (45.0%) borderline, and 11 of 14 (78.6%) malignant tumors, suggesting that the dual-marker panels of TCN1 and HOXB13 might be helpful in classifying borderline and malignant tumors. Although expression of TCN1 alone was present in all malignant and 34 of 40 (85.0%) borderline tumors, a combined panel with HOXB13 excluded some benign cases and was a better discriminant for a significant proportion of borderline and malignant tumors. © 2011 Springer Science+Business Media, LLC.
Source Title: Breast Cancer Research and Treatment
URI: http://scholarbank.nus.edu.sg/handle/10635/110148
ISSN: 01676806
DOI: 10.1007/s10549-011-1555-6
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

20
checked on Nov 21, 2022

WEB OF SCIENCETM
Citations

16
checked on Sep 28, 2021

Page view(s)

126
checked on Nov 24, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.